Literature DB >> 23934522

The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud's phenomenon.

Slavica R Pavlov-Dolijanovic1, Nemanja S Damjanov, Nada Z Vujasinovic Stupar, Snezana Baltic, Dragan D Babic.   

Abstract

The aim of this study is to assess the prognostic value of major provisional criteria for the development of systemic sclerosis (SSc) in primary Raynaud's phenomenon (RP) patients. We retrospectively studied the chart of 497 patients with primary RP in whom anticentromere (ACA) and antitopoisomerase I (ATA) antibodies tests and a capillary reading were available. Sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratios (LHR+), negative likelihood ratios (LHR-), odds ratio (OR), and area under the receiver operating characteristics curve (AUC) of those criteria were assessed to predict the development of SSc. During the average follow-up of 2.3 ± 1.9 years, 159 (32 %) patients evolved to SSc, 245 (49.3 %) evolved to other connective tissue diseases, and 93 (18.7 %) patients did not progress. The SSc pattern predicted SSc satisfactorily (LHR+ 4.12, LHR- 0.07, OR 63, AUC 0.819; P < 0.001). ACA were not significantly associated with the development of SSc (LHR+ 1.19, LHR- 0.9, OR 1.32, AUC 0.538, P = 0.156). ATA were significantly associated with the development of SSc (LHR+ 9.32, LHR- 0.67, OR 15.13, AUC 0.777; P < 0.001). Both SSc pattern and ACA or ATA were significantly associated with the development of SSc (LHR+ 2.98, LHR- 0.70, OR 4.2, AUC 0.674; P < 0.001 vs. LHR+ 16, LHR- 0.68, OR 24, AUC 0.819; P < 0.001, respectively). SSc pattern or ATA as independent risk factors, as well as following two parameters together (SSc pattern and ATA or SSc pattern and ACA) were good predictors for the development of SSc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23934522     DOI: 10.1007/s00296-013-2844-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  26 in total

Review 1.  Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria.

Authors:  M Mosca; R Neri; S Bombardieri
Journal:  Clin Exp Rheumatol       Date:  1999 Sep-Oct       Impact factor: 4.473

Review 2.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 3.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

4.  Anticentromere antibody--clinical associations. A study of 44 patients.

Authors:  P Caramaschi; D Biasi; T Manzo; A Carletto; F Poli; L M Bambara
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

5.  Timing of transition between capillaroscopic patterns in systemic sclerosis.

Authors:  Alberto Sulli; Carmen Pizzorni; Vanessa Smith; Giuseppe Zampogna; Francesca Ravera; Maurizio Cutolo
Journal:  Arthritis Rheum       Date:  2012-03

6.  Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon.

Authors:  Slavica Pavlov-Dolijanovic; Nemanja S Damjanov; Roksanda M Stojanovic; Nada Z Vujasinovic Stupar; Dejana M Stanisavljevic
Journal:  Rheumatol Int       Date:  2011-09-08       Impact factor: 2.631

7.  Clinical and serological heterogeneity in patients with anticentromere antibodies.

Authors:  Shoji Miyawaki; Hiroko Asanuma; Susumu Nishiyama; Yasuhiko Yoshinaga
Journal:  J Rheumatol       Date:  2005-08       Impact factor: 4.666

8.  Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients.

Authors:  D Alarcón-Segovia; M H Cardiel
Journal:  J Rheumatol       Date:  1989-03       Impact factor: 4.666

9.  Patients with anticentromere antibodies, clinical features, diagnoses and evolution.

Authors:  P G Vlachoyiannopoulos; A A Drosos; A Wiik; H M Moutsopoulos
Journal:  Br J Rheumatol       Date:  1993-04

10.  Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities. A six-year follow-up study.

Authors:  P Zufferey; M Depairon; A M Chamot; M Monti
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

View more
  3 in total

Review 1.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

2.  Autoantibodies versus Skin Fibrosis Extent in Systemic Sclerosis: A Case-Control Study of Inverted Phenotypes.

Authors:  Ashley Tieu; Benjamin Chaigne; Bertrand Dunogué; Jérémie Dion; Alexis Régent; Marion Casadevall; Pascal Cohen; Paul Legendre; Benjamin Terrier; Nathalie Costedoat-Chalumeau; Claire Le Jeunne; Luc Mouthon
Journal:  Diagnostics (Basel)       Date:  2022-04-24

Review 3.  Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification.

Authors:  Changyi Yang; Shunli Tang; Dingxian Zhu; Yingguo Ding; Jianjun Qiao
Journal:  Front Med (Lausanne)       Date:  2020-11-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.